Syed A. Ahmad, Director at University of Cincinnati Cancer Center and Chief of Surgical Oncology at University of Cincinnati, shared on X:
“Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double – blind, placebo – controlled trial – The Lancet Gastroenterology and Hepatology.”
Title: Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial
Authors: Sheraz Yaqub, Morten Valberg, Bjørn Atle Bjørnbeth, Jon-Helge Angelsen, Kristoffer Watten Brudvik, Ina Andrassy Eilertsen, Richard Fristedt, Claus Wilki Fristrup, Stefan Gilg, Oskar Hemmingsson, Bengt Isaksson, Ingebjørg Soterud Juel, Anders Riegels Knudsen, Peter Nørgaard Larsen, Kim Erlend Mortensen, Inge Christoffer Olsen, Per Sandström, Oddvar Mathias Sandvik, Ernesto Sparrelid, Helena Taflin, Ragnhild A Lothe, Kjetil Taskén
